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OBJECTIVES: The objectives of this study were to determine the prevalence and
patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients
experiencing virological failure on raltegravir-based ART and the impact on
susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir).
PATIENTS AND METHODS: Data were collected from 502 treatment-experienced
patients failing a raltegravir-containing regimen in a multicentre study. Reverse
transcriptase, protease and integrase were sequenced at failure for each patient.
INSTI resistance-associated mutations investigated were those included in the last
ANRS genotypic algorithm (v23).
RESULTS: Among the 502 patients, at failure, median baseline HIV-1 RNA (viral
load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of
five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1
subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most
frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and
Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all
INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir,
34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to
raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to
dolutegravir in 64% of cases. High HIV-1 viral load at failure (P < 0.001) and low
genotypic sensitivity score of the associated treatment with raltegravir (P < 0.001)
were associated with the presence of raltegravir-associated mutations at failure.
Q148 mutations were selected more frequently in B subtypes versus non-B subtypes
(P = 0.004).
CONCLUSIONS: This study shows that a high proportion of viruses remain
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